Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015
Mary B. Daly(Fox Chase Cancer Center), Susan Darlow(National Comprehensive Cancer Network), P. Kelly Marcom(Duke University), Gwen Reiser(University of California San Diego), Meagan Farmer(University of Alabama at Birmingham), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Jeffrey N. Weitzel(Cancer Genetics (United States)), Tuya Pal(Vanderbilt University Medical Center), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Michael P. Berry(St. Jude Children's Research Hospital), Kristen M. Shannon(Massachusetts General Hospital), Robert Pilarski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Wendy Kohlmann(University of Utah), Nicoleta Voian(Roswell Park Comprehensive Cancer Center), Allison W. Kurian(Stanford University), Sofía D. Merajver(University of Michigan), Myra Wick(WinnMed), Rashmi Kumar(University of London), Georgia L. Wiesner(The University of Western Australia), Saundra S. Buys(University of Utah), Lisa Madlensky(UC San Diego Health System), Jennifer E. Axilbund(Johns Hopkins University), Elizabeth M. Swisher(University of Washington), Huma Q. Rana(Dana-Farber Brigham Cancer Center), Alison J. Whelan(Barnes-Jewish Hospital), Catherine Klein(University of Utah), Susan Friedman(Facing Our Risk of Cancer Empowered), Mary A. Dwyer(National Comprehensive Cancer Network), Kenneth Offit(Memorial Sloan Kettering Cancer Center), Seema Khan(University of Colorado Cancer Center), Judy E. Garber(Dana-Farber Cancer Institute)
Cited by 293
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.6k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k